Patient-controlled epidural analgesia (PCEA), first described by Gambling et al, is an established mode of epidural drug delivery that is safe and effective 1, 2 . Patients who receive PCEA are less likely to require anaesthetic interventions, require lower doses of local anaesthetic and have less motor block than those who receive continuous epidural infusion 3 . Although PCEA is an effective and well-accepted method of obstetric analgesia 4 , there is still debate about the optimal PCEA regimen for the best pain relief and high patient satisfaction 5 . Missant et al found that PCEA with a basal infusion provides effective analgesia that reduced the anaesthetic workload and local anaesthetic consumption compared with PCEA without a basal infusion 6 . Bremerich et al found that PCEA with a basal infusion was more effective than demand-only PCEA, without increasing the consumption of local anaesthetic 7 . Local anaesthetic requirements are also influenced by factors such as the stage and progress of labour 9, 10 .
Computer-integrated patient-controlled epidural analgesia (CIPCEA) is programmed to analyse local anaesthetic use across the last hour and adjusts the background infusion rate according to the algorithm ( 
SUMMARY
Computer-integrated patient-controlled epidural analgesia (CIPCEA) is a novel epidural drug delivery system. It automatically adjusts the background infusion based on the individual parturient's need for analgesia as labour progresses.
In this randomised controlled trial, we compared the local anaesthetic consumption by parturients using either CIPCEA or patient-controlled epidural analgesia with a moderate basal infusion (PCEABI) of 5 ml/hour. We recruited 60 parturients after receiving ethics committee approval. Group CIPCEA (n=30) received a similar patient-controlled epidural analgesia regimen but the computer integration titrated the background infusion to 5, 10 or 15 ml/hour if the patient required respectively one, two or three demand boluses in the previous hour. The background infusion was decreased by 5 ml/hour if there was no demand in the previous hour. Group PCEABI received patient-controlled epidural analgesia with a basal infusion of 5 ml/hour. The sample size was calculated to show equivalence in local anaesthetic use.
The time-weighted consumption of local anaesthetic was similar in both groups (mean difference 0.3 mg/hour, 95% confidence interval: -1.8, 1.3, P=0.755). The CIPCEA group had higher maternal satisfaction scores: mean (SD) 94.8 (6.32) vs. 85.5 (9.41), P=0.0001. The CIPCEA group had a higher infusion rate during the second stage of labour (mean (SD) 7.0 (4.1) ml/hour vs. 4.5 (1.5) ml/hour, P=0.008), but did not have a longer duration of this stage. There were no differences between the groups in obstetric or foetal outcomes or side-effect profiles.
The CIPCEA system has similar time-weighted, hourly consumption of local anaesthetic to PCEABI and may increase patient satisfaction.
CSE=intrathecal fentanyl 15 μg + ropivacaine 2 mg + epidural 1.5% lignocaine 3 ml connected via two-way communications using RS232 serial ports to a modified infusion pump (IVAC P700, Alaris, UK) 11 . This set-up was heavy and not portable.
No infusion
We have now developed a portable epidural drug delivery system replacing the laptop with a personal digital assistant using Windows Mobile system ( Figure 2 ). In the previous study conducted at this centre, which compared CIPCEA with demand-only PCEA, we showed that CIPCEA did not increase the use of local anaesthetic but did increase patient satisfaction 8 . However, demand-only PCEA is arguably not the method of choice and PCEA including a non-adjusting moderate basal infusion (PCEABI) may be a better comparison 12 . In this study, we compared CIPCEA with PCEABI of 5 ml/hour for the maintenance of labour epidural analgesia following a combined spinal epidural (CSE) technique. Our primary outcome was the timeweighted, hourly consumption of local anaesthetic for the duration of labour epidural analgesia. We also assessed secondary outcomes such as incidence of breakthrough pain, duration of labour analgesia, infusion rate at delivery, side-effects and maternal satisfaction scores.
MATERIALS AND METHODS
The hospital research ethics committee approved this study and informed consent was obtained from each subject during early labour. We recruited 60 ASA I nulliparous term parturients who had requested epidural analgesia into this randomised, double-blind controlled trial. We included parturients in established labour with cervical dilatation <5 cm and with baseline pain score >5 (on a 0 to 10 visual analogue scale (VAS): 0=no pain, 10=worst pain imaginable), who had a singleton foetus with vertex presentation at term and no pregnancy-related complications. We excluded parturients who had received parenteral opioid within two hours.
Each subject received a preload of intravenous Ringer's Lactate solution 500 ml. Baseline pain scores were obtained and systolic blood pressure, measured in the right brachial artery using a non-invasive blood pressure monitor (Dinamap, Critikon, FL, USA) with the parturient supine with left uterine displacement, was recorded. The use of cervical prostaglandin E2, intravenous oxytocin and the cervical dilatation prior to the CSE were recorded.
The CSE technique was performed with the parturient seated. After the epidural space was located with a 17-gauge Weiss needle using loss of resistance to <2 ml of saline, dural puncture was performed with a 27-gauge pencil point spinal needle (Espocan, B Braun, Melsungen, Germany) through the epidural needle. Ropivacaine 2 mg and fentanyl 15 µg diluted with normal saline to a total volume of 2 ml was injected intrathecally over 15 seconds, with the orifice of the spinal needle facing in a cephalad direction. A multi-orifice epidural catheter was inserted 3 to 4 cm into the epidural space and tested with 3 ml of 1.5% lignocaine to exclude intrathecal placement. In the event of significant motor block (inability to flex the knees) or a reduction of >20% in systolic blood pressure, the subject was to be withdrawn from the study due to suspected intrathecal catheter placement. Subjects who had blood or cerebrospinal fluid aspirated from the catheter were also withdrawn from the study.
We randomly allocated subjects using sealed opaque envelopes into two groups using computergenerated random number tables. Group PCEABI received a PCEA regimen using a commercially available epidural infusion pump with a 5 ml/hour basal infusion, a demand bolus of 5 ml of ropivacaine 0.1% with fentanyl 2 µg/ml, a lockout interval of 10 minutes and a maximum dose of 20 ml/hour (Rythmic™ Pump Micrel Medical Devices SA, Pallini, Greece).
Group CIPCEA received the same local anaesthetic and opioid solution using a novel PCEA regimen. The starting background infusion rate was 0 ml/hour but the computer integration allowed the infusion to increase by 5 ml/hour if the subject required one demand bolus in the previous hour. If the subject required two demand boluses in the previous hour, the infusion increased to 10 ml/hour. The maximum infusion rate was limited to 15 ml/hour and further demand boluses would activate an alarm to alert the attending anaesthetist to review the patient. On the other hand, if the subject did not receive a demand bolus during the previous hour, the infusion decreased by 5 ml/hour.
The patients were blinded to their group allocation and were not told the epidural regimen to which they were assigned. Both groups were given a hand-held device and instructed to self-administer an epidural bolus dose by pressing the button. They were instructed to activate an epidural bolus when they experienced mild to moderate pain, before the pain intensity became severe.
Subjects who did not obtain satisfactory pain relief (VAS <3) 15 minutes after the CSE were deemed to have a failed block. In this event rescue medication was to be delivered via the epidural catheter and the subject removed from the study.
An anaesthetist who was not involved in performing the block collected the following data at Anaesthesia and Intensive Care, Vol. 37, No. 1, January 2009 zero, 15 and 30 minutes after the CSE technique and at two, four, six, eight, 10 and 12 hours for parturients who had not delivered: systolic blood pressure; maternal and foetal heart rates; pain scores using VAS; sensory level (tested with ice); side-effects: lower limb motor block using a modified Bromage score (0=no motor block, 1=inability to raise extended leg, able to flex knee, 2=inability to flex the knee, able to move the foot only, 3=inability to flex the ankle joint, unable to move the foot or knee); pruritus; shivering; hypotension; nausea; vomiting and foetal bradycardia.
Breakthrough pain was defined as failure of the regimen to provide adequate pain relief, necessitating unscheduled epidural supplementation by the anaesthetist prior to delivery. The attending anaesthetist assessed the pain scores and gave 0.2% ropivacaine 5 ml. If the pain score remained above 3 despite administering a total of up to 20 ml of 0.2% ropivacaine (in 5 ml aliquots over 30 minutes), the catheter was labeled as ineffective and the subject excluded from analysis. After breakthrough pain was relieved, parturients continued their allocated regimen.
The foetal heart rate (from a continuous external cardiotocogram) was assessed by the attending obstetrician who was blinded to the drugs and regimen being administered. The time of delivery, mode of delivery, neonatal Apgar scores and overall maternal satisfaction with neuraxial analgesia were assessed and recorded within two hours of delivery using a 0 to 100 scale (0=very dissatisfied, 100=very satisfied).
The null hypothesis in this equivalence trial stated that the hourly consumption of anaesthetic solution during PCEA with basal infusion was less than that during CIPCEA. The CIPCEA uses a variable background infusion depending on the parturient's need and we propose that this would not increase the consumption of local anaesthetic. CIPCEA was considered to be at least equivalent to PCEA with a basal infusion if the 95% confidence interval (CI) of the difference in local anaesthetic consumption did not exceed 30% of the absolute hourly infusion rate. We assumed the use of local anaesthetic with PCEABI (demand plus 5 ml/hour) to be 7.5 mg/hour 13 . Asample size of 30 per group was needed to reject the null hypothesis (of nonequivalence) with a power of 80% and significance level of 5% if the specified alternative hypothesis (of equivalence) was true. The 95% CI and P value are reported. Analysis of dichotomous data was performed using Chi-square testing. The Student t-test and Mann Whitney U-test were employed for parametric and non-parametric data respectively. The Kaplan-Meier survival technique was used to compare groups for duration of analgesia. All data and statistical analyses were performed using SPSS version 13.0 (Chicago, IL, USA).
RESULTS
There were no differences between the two groups in the demographic and baseline obstetric data ( Table 1 ). All parturients had pain scores <3 by 15 minutes after CSE and there were no failed blocks or ineffective catheters. Values are n (proportion), mean (SD) or median [range] . No significant differences were found between the two groups. Values are tabulated from parturients who experienced breakthrough pain with CIPCEA group, n=2 and the PCEABI group, n=3. CIPCEA=computer integrated patient-controlled epidural analgesia, PCEABI=patientcontrolled epidural analgesia with basal infusion, VAS=visual analogue scale. Values are n (percentage). CIPCEA=computer integrated patient-controlled epidural analgesia, PCEABI=patient-controlled epidural analgesia with basal infusion. The time-weighted consumption of epidural local anaesthetic from the time of induction of the CSE to the time of delivery, including local anaesthetic used to treat breakthrough pain, was similar for the CIPCEA group (mean [SD] 9.0 [3.7] Table 2) .
The CIPCEA and PCEABI groups did not differ significantly in the incidence of breakthrough pain ( Table 3 ). The mean duration of analgesia in the CIPCEA group did not significantly differ from the PCEABI group (Figure 3 ). The CIPCEA group had higher maternal satisfaction scores than the PCEABI group (mean [SD] 94.8 [6.32] vs. 85.5 [9.41] , P=0.0001). The CIPCEA group had a significantly higher infusion rate at the time of normal vaginal or instrumental delivery compared with the PCEABI group. Four parturients in the CIPCEA group and two in the PCEABI group had the epidural infusion stopped by the obstetric team during the second stage of labour.
None of the parturients developed significant motor block, although ambulation was not attempted by all parturients. There was no difference between groups in the serial pain scores during the first 10 hours ( Figure 4) and no difference in the sensory block level or side-effect profiles ( Table 4 ). Mode of delivery, foetal weight and Apgar scores did not differ significantly ( Table 2) .
DISCUSSION
In this study, we demonstrated that CIPCEA with a variable basal infusion results in a similar timeweighted, hourly consumption of local anaesthetic when compared to PCEABI. Although CIPCEA is able to deliver a variable background infusion, this only starts as the labour progresses and it is initiated by the parturient. This potentially minimises local anaesthetic use in early labour when pain scores are lower and requirement is less 10 . We found a higher infusion rate in the CIPCEA group during the second stage of labour. We speculate that this might reduce perineal pain and improve maternal satisfaction.
The parturients who used CIPCEA had modestly higher satisfaction scores. This was a secondary outcome and is a subjective assessment of the overall epidural labour analgesia, so the clinical significance of this finding is uncertain. The breakthrough pain rate, pain scores in the first stage of labour and total dose of local anaesthetic used did not significantly differ between groups. In other studies, the presence of a background infusion has improved pain scores and reduced supplementation 7, 14 . In this study, there was no increase in the duration of the second stage of labour or increase in instrumental delivery, despite the higher epidural infusion rate. Further studies using cumulative hourly consumption and pain scores during the second stage of labour may help to confirm if maternal satisfaction is increased with CIPCEA and if so, elucidate the reasons.
The role of a basal infusion in PCEA regimens has been investigated with differing results. The PCEABI regimen may lead to an equal or greater consumption of anaesthetic solution than demand-only PCEA, without improving comfort and satisfaction of parturients 15, 16 . However, demand-only PCEA has been found to increase the need for supplementary top-ups 14 . In our previous study, the demandonly PCEA method was associated with a 35% breakthrough pain rate, which compares with 10% associated with PCEABI in this study. This further supports that PCEA with a moderate basal infusion provides a better comparison to CIPCEA. The CIPCEA group demonstrated a 6.7% breakthrough pain rate. Although our study was not designed to show a significant difference in breakthrough pain rates, if an apparent 33% relative risk reduction in rate is confirmed in future studies, this would prove clinically important in reducing anaesthetic workload and increasing maternal satisfaction.
In this study, two parturients receiving CIPCEA experienced breakthrough pain, which occurred about three hours after initiation of CSE, at 3 cm and 5 cm cervical dilatation respectively. The background infusion at the time was 15 ml/hour. When the patients demanded further doses, the system alarm alerted the anaesthetist. Both women complained of perineal pain and epidural top-ups of 0.2% ropivacaine 10 and 15 ml respectively were administered, with resolution of pain. The first patient had an instrumental delivery, while the second patient had a normal vaginal delivery. It is possible that the absence of an initial basal infusion in the CIPCEA algorithm may result in recession of sensory block such that successive demand boluses are inadequate once pain increases due to labour augmentation or progress. However, incorporating an initial basal infusion into the CIPCEA algorithm could increase local anaesthetic use, so further research is necessary.
By miniaturising the hardware from laptop computer to a personal digital assistant, our centre has made the CIPCEA system lightweight, portable and convenient for use in a busy obstetric unit. We believe the CIPCEA regimen combines the advantages of a demand-only PCEA regimen (decreased local anaesthetic consumption) and PCEA with a basal infusion (decreased breakthrough pain rate and better patient satisfaction).
In conclusion, the CIPCEA regimen we studied resulted in similar local anaesthetic consumption to a PCEA with moderate basal infusion regimen. It was associated with a higher local anaesthetic infusion rate at the time of normal vaginal and instrumental delivery, but this did not appear to influence the duration of the second stage of labour and higher satisfaction scores were reported. Future research of this novel epidural delivery program will include redefining the algorithm to provide optimal analgesia and incorporating the regimen into a portable pump to facilitate convenience in a busy obstetric delivery suite.
